Imperial College London

DrCarolinaHerrera

Faculty of MedicineDepartment of Infectious Disease

Advanced Research Fellow
 
 
 
//

Contact

 

carolina.herrera

 
 
//

Location

 

460 (Shattock Group)Medical SchoolSt Mary's Campus

//

Summary

 

Summary

I am a Senior Research Fellow in the Section of Immunology of Infection.  I obtained my BSc in Chemistry and my PhD in Biochemistry, working on the role of adenosine and adenosine deaminase in immunodeficiencies, at the University of Barcelona, Spain. I then joined the group of Prof. John P. Moore at the Weill Medical College of Cornell University, New York, USA.  As a Postdoctoral Fellow, I had the opportunity to make my first steps in the field of HIV working in the areas of neutralizing antibodies and CCR5 co-receptor.

My primary research interests are mucosal infection and inflammation. Using ex vivo tissue models, I study mucosal responses during transmission of HIV/SIV, HCV, and Zika virus. These primary tissue models also allow pre-clinical evaluation of prevention strategies, including pre-exposure prophylaxis and vaccine candidates. I have recently expanded the potential of the ex vivo tissue models to investigate inflammation and associated pathologies such as Inflammatory Bowel Disease.

During the last 10 years, I have been funded as PI or co-investigator by amfAR, HVTN-CHAVI, EU Commission FP7 Health 2012 Innovation, EDCTP, NIH, Canadian Institute for Health Research, Manitoba Health Research, Henry Jackson Foundation, Pfizer, Gilead, Merck and CHAIN Biotechnology.

Publications

Journals

Herrera C, Cottrell ML, Prybylski J, et al., 2022, The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans, Iscience, ISSN:2589-0042

Reuschl A-K, Mesner D, Shivkumar M, et al., 2022, HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells., Cell Rep, Vol:39

Herrera C, Veazey R, Lemke MM, et al., 2022, Ex vivo evaluation of mucosal responses to vaccination with ALVAC and AIDSVAX of non-human primates, Vaccines, Vol:10, ISSN:2076-393X

Mora-Peris B, Keegan MR, Penchala SD, et al., 2021, Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial, Hiv Research & Clinical Practice, Vol:22, ISSN:2578-7489, Pages:151-159

Herrera C, Harman S, Aldon Y, et al., 2021, The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate, Aids, Vol:35, ISSN:0269-9370, Pages:1907-1917

More Publications